Is BEAM or BLTE more undervalued in 2026?

CirclFi compares Beam Therapeutics Inc. (BEAM) and Belite Bio, Inc (BLTE) using 13 institutional-grade valuation models. BEAM has a Quality of Company score of 6.4/10 while BLTE scores 4.7/10.

Which is a better buy — BEAM or BLTE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BEAM and BLTE valuations compare?

BEAM at $32.80 and BLTE at $148.00 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BEAM vs BLTE Valuation Comparison 2026 — Intrinsic Value Analysis

BEAM

Biotechnology

Beam Therapeutics Inc.

Quality

6.4

out of 10

Value Trap

SAFE

Price

$32.80

Last close

Models

12/13

Active

BLTE

Biotechnology

Belite Bio, Inc

Quality

4.7

out of 10

Value Trap

SAFE

Price

$148.00

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	BEAM Fair Value	BEAM Upside	BLTE Fair Value	BLTE Upside
Bayesian DCF	Intrinsic	$10.45	-68.1%	$49.41	-66.6%
Earnings Power Value	Intrinsic	$15.21	-43.9%	$77.24	-52.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BEAM vs BLTE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BEAM vs BLTE — Which Stock Is More Undervalued?

BEAM scores higher with a 6.4/10 quality rating vs BLTE's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Beam Therapeutics Inc. (BEAM) and Belite Bio, Inc (BLTE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BEAM currently trades at $32.80 with a QOC of 6.4/10, while BLTE trades at $148.00 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).